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Abstract
Antisense oligodeoxynucleotides (asODN) are therapeutic agents that are designed to inhibit the expression of disease-
related genes. However, their therapeutic use may be hindered due to their rapid clearance from blood and their inefficiency
at crossing cell membranes. Cationic liposome complexes have been used to enhance the intracellular delivery of asODN in
vitro; however, this type of carrier has unfavorable pharmacokinetics for most in vivo applications. Significant therapeutic
activity of cationic liposomal asODN following systemic administration has not been demonstrated. In an effort to develop
improved liposomal carriers for asODN for in vivo applications, we have evaluated the physical characteristics of two
formulations which represent alternatives to cationic liposome^asODN complexes: asODN passively entrapped within
neutral liposomes (PELA) and asODN formulated in a novel coated cationic liposomal formulation (CCL). Our results
confirm that PELA can be extruded to small diameters that are suitable for intravenous administration. PELA are stable in
human plasma; however, the incorporation efficiency is relatively low (V20%). The CCL formulation can also be extruded
to small diameters (6 200 nm), with significantly higher (80^100%) incorporation efficiency and are stable in 50% human
plasma at 37‡C. A liposomal carrier for asODN with these characteristics may provide a significant therapeutic advantage
over free asODN for some therapeutic applications. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Antisense oligodeoxynucleotides (asODN) can be
used to decrease the expression of disease-related
genes by inhibiting the translation of the mRNA of
the target gene, through several possible mechanisms
(reviewed in [1]). However, asODN must cross plas-
ma membranes in order to reach their site of action
in the cell and in vitro, liposomal carriers are often
used to increase their intracellular delivery.
Di¡erent liposomal formulations have been used
to deliver asODN to cells ; however, the most widely
used formulation at present consists of pre-formed
cationic liposomes, with or without DOPE, mixed
with asODN [2]. In vitro, these liposomes have
been shown to increase the intracellular delivery of
asODN, thus increasing the concentration and activ-
ity of asODN. The electrostatic interaction between
the positively charged lipid and the negatively
charged asODN results in the formation of lipid^
asODN complexes or lipoplexes. Lipoplexes are usu-
ally formulated with excess positive charge in order
to mediate interaction with cell membranes which
carry a net negative charge. This type of formulation
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is very e⁄cient at incorporating asODN and delivery
to cells in vitro and have been shown in many sys-
tems to be necessary for an antisense activity [2,3]. In
vivo, the utility of lipoplexes is less clear, and there
are no examples that convincingly demonstrate the
activity of asODN following intravenous administra-
tion. This is because lipoplexes have been optimized
for in vitro applications, and in vivo their large size
and excess positive charge result in unfavorable
pharmacokinetics, mainly due to rapid uptake into
tissues of the mononuclear phagocytic system (MPS).
Since asODN are hydrophilic, they can be pas-
sively encapsulated within the aqueous space of
non-cationic liposomes, and this method has been
used in several published reports [4^10]. The main
advantage of this type of carrier is that the liposomes
can be reduced to small diameters and there is no
positive charge to trigger opsonization by serum pro-
teins and MPS uptake. These properties make neu-
tral liposomes attractive candidates for intravenous
delivery of hydrophilic drugs like asODN. In addi-
tion, polyethylene glycol (PEG) can be grafted onto
the liposome surface, which decreases the uptake of
the liposomes into the MPS, leading to increased
circulation times and enhanced localization of lipo-
somal contents in diseased tissues [11^15].
An important limitation to passive encapsulation
of asODN within the aqueous space of liposomes is
the poor incorporation e⁄ciency, especially within
small (6 200 nm) liposomes. For example, hydration
of a dried lipid ¢lm (DPPC/CHOL) with a concen-
trated solution of a 15-mer phosphodiester asODN
resulted in only 3% incorporation following extru-
sion through a 200 nm unipore ¢lter [4]. In another
study, liposomes encapsulating a 15-mer asODN
were prepared using the reverse phase evaporation
method and 10% incorporation e⁄ciency was re-
ported into liposomes 170 nm in diameter [7]. Other
studies fail to present details describing the incorpo-
ration e⁄ciency, the asODN to lipid ratio, or lipo-
some size [8,10], and these are all important param-
eters to consider in the development and use of a
liposomal carrier for asODN. Even when novel pro-
tocols are developed which increase the encapsula-
tion e⁄ciencies of oligonucleotides to 50^70%, the
liposome size is not reported [5,16]. An additional
criticism is that most of these studies made no e¡ort
to distinguish entrapped asODN from that passively
associated with the outside of the liposomal mem-
brane.
The purpose of the present study was twofold:
¢rst, we wanted to determine the encapsulation e⁄-
ciency of asODN within the aqueous space of small
(6 200 nm) neutral liposomes containing PEG^
DSPE. Our results indicate that the addition of 2^5
mol% PEG^DSPE into neutral liposomes approxi-
mately doubles the incorporation e⁄ciency of
asODN from less than 10% to 20%. The second pur-
pose of the study was to develop and characterize a
liposomal carrier for asODN containing cationic lip-
id, which would be suitable for intravenous admin-
istration. By using a method that optimizes the
charge interaction between the asODN and the cat-
ionic lipid, combined with a method that provides an
outer coating of neutral lipid, we have been able to
produce a liposomal carrier which is very e⁄cient at
incorporating asODN (80^100%), has a small diam-
eter (6 200 nm), and is stable in human plasma. In
this paper we provide a detailed description of PEG-
containing liposomes passively entrapping asODN
(PELA) and a novel formulation containing cationic
lipid^asODN particles coated with PEG^DSPE and
neutral lipids (CCL).
2. Materials and methods
2.1. Materials
Partially hydrogenated egg phosphatidylcholine io-
dine number 40 (PC40) and poly(ethyleneglycol)
(molecular mass 2000) covalently attached to distear-
oylphosphatidylethanolamine (PEG^DSPE) were
generous gifts from SEQUUS Pharmaceuticals
(Menlo Park, CA) and have been described elsewhere
[17,18]. Cholesterol (CHOL) and 1,2-dioleoyl-3-tri-
methylammonium-propane (DOTAP) were pur-
chased from Avanti Polar Lipids (Alabaster, AL).
Sepharose CL-4B, Na-125I (560^625 MBq/Wg iodine),
and scintillation £uor/aqueous counting scintillant
(ACS) were purchased from Amersham Pharmacia
Biotech (Piscataway, NJ). Iodogen was purchased
from Pierce Chemical Co. (Rockford, IL). Bio-Spin
6 chromatography columns were purchased from
Bio-Rad (Hercules, CA). Human plasma, containing
sodium citrate as an anticoagulant, was obtained
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from Canadian Blood Services (Edmonton, AB).
Metrizamide (Grade 1) was purchased from Sigma
Chemical Co. (St. Louis, MO). Cholesteryl-[1,2-3H-
(N)]-hexadecyl ether ([3H]CHE), 1.48^1.22 TBq/
mmol, was purchased from New England Nuclear
(Mississauga, ON). [Q-32P]Adenosine-5P-triphosphate
([Q-32P]ATP) (110^167 TBq/mmol) was purchased
from ICN Pharmaceuticals (Irvine, CA) or the De-
partment of Biochemistry DNA Core Services Labo-
ratory at the University of Alberta (Edmonton, AB).
T4 polynucleotide kinase was purchased from Gibco
BRL (Burlington, ON). A phosphorothioate asODN
complementary to the MDR1 initiation codon (5P-
GTCCCCTTCAAGATCCAT-3P) was synthesized
by the University Core DNA Services Laboratory
at the University of Calgary (Calgary, AB). For
most experiments PEI-cellulose chromatography
sheets were purchased from J.T. Baker (Phillipsburg,
NJ). Nuclepore polycarbonate ¢lters for extrusion
were purchased from Corning Costar (Kennebunk,
ME). All other chemicals were of analytical grade
quality.
2.2. Preparation of radiolabeled oligodeoxynucleotides
[32P]asODN and [125I]asODN were prepared and
used as tracers in order to follow the incorporation
of asODN within the di¡erent liposomal formula-
tions. Phosphorothioate asODNs were labeled with
125I using Iodogen similar to the method described
by Piatyszek et al. [19]. A 1-ml reaction vial was
coated with a thin ¢lm of Iodogen by dissolving ap-
proximately 1 mg of Iodogen in chloroform and then
drying the solution under a stream of nitrogen. Next,
100^500 Wg asODN in 50 Wl along with 300 Wl of 0.35
M sodium acetate (pH 4.0) and 185 MBq (2300
pmol) of 125I in a volume of 50 Wl were added to
the vial and incubated at 40‡C for 45 min. Free
125I was removed on a Sephadex G-15 column. Dial-
ysis or precipitation of the asODN, followed by re-
hydration, resulted in less than 5% free 125I. The
speci¢c activity of the [125I]asODN was approxi-
mately 4 MBq/nmol. This protocol results in the
125I label being covalently attached at the C-5 posi-
tion of cytidine bases [19,20].
In some experiments, [32P]asODNs were also used
in order to determine incorporation e⁄ciency. T4
polynucleotide kinase and forward labeling bu¡er
were used as outlined by the manufacturer. Free
[Q-32P]ATP was separated using a Bio-Spin 6 column.
The speci¢c activity of labeled phosphorothioate
asODNs was approximately 9 MBq/nmol. Contami-
nation of the sample by [Q-32P]ATP was negligible as
determined by thin-layer chromatography.
2.3. Preparation of liposomes passively entrapping
asODN
Passively entrapped liposomal asODN (PELA)
were prepared by a method similar to that described
by Thierry et al. [5,16]. PC40/CHOL/PEG^DSPE
were mixed at a 2:1:0, 2:1:0.04, 2:1:0.08 or
2:1:0.1 molar ratio (3 Wmol total phospholipid) in
CHCl3 (along with a trace of [3H]CHE) and dried
to a thin ¢lm by rotary evaporation. Nine Wl of a
10 mg/ml solution of asODN, determined by absor-
bance at 260 nm (A260), in distilled deionized water
(ddH2O), plus trace [125I]asODN, was added, and the
¢lm was hydrated overnight at 4‡C. The following
day an additional 9 Wl of 10 mg/ml asODN (includ-
ing trace [125I]asODN) was added and the tube was
vortexed vigorously for 30 s. Next, 18 Wl of Hepes
bu¡er (25 mM Hepes, 140 mM NaCl, pH 7.4) was
added and the sample was vortexed vigorously again.
After a 2-h incubation at room temperature the tubes
were sonicated for 3 min in a bath sonicator. An
additional 450 Wl of Hepes bu¡er was added and
the liposomes were extruded with a syringe-tip ex-
truder through progressively smaller polycarbonate
¢lters (800^200 nm). In some experiments, prior to
the extrusion step, liposomes were subjected to 10
freeze (liquid N2) and thaw (40‡C) cycles following
sonication. Liposome size was determined by dynam-
ic light scattering using a Brookhaven B190 submi-
cron particle analyzer (Brookhaven Instruments,
Holtsville, NY). Free asODN was separated from
encapsulated asODN by passing the mixture down
a Sepharose CL-4B column (1U20 cm).
2.4. Preparation of coated cationic liposomes
Bligh and Dyer extractions [21], using the cationic
lipid 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP) and an 18-mer phosphorothioate asODN,
were carried out in a similar method to that used for
plasmid DNA [22,23]. DOTAP was diluted in 0.25 ml
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CHCl3, and 0.52 ml of MeOH was added followed
by 0.25 ml of asODN (the amount was measured by
A260) diluted in ddH2O (unless otherwise speci¢ed).
Following 30 min at room temperature, 0.25 ml of
CHCl3 and 0.25 ml of ddH2O were added and the
tubes were centrifuged for 7 min at 830Ug. Follow-
ing centrifugation, the phases were separated and
radioactivity measured, or the A260 was measured
in the aqueous phase, to determine the amount of
asODN extracted.
Following extraction and removal of the aqueous
phase, PC40, CHOL, and PEG^DSPE were added to
the organic phase at the indicated ratios. ddH2O was
then added (to give 10^30 mM lipid concentration in
the water volume), and the tube was vortexed vigo-
rously (20 s) and then sonicated for 1 min to produce
a stable emulsion. CHCl3 was then evaporated under
vacuum (V500 mmHg) on a rotary evaporator until
a gel phase was reached. Subsequent evaporation
lead to the inversion of the system from a gel to a
liquid. During this procedure we hypothesize that the
DOTAP^asODN particles have been coated with
non-cationic lipids. The following experiments de-
scribe the characterization of coated cationic lipo-
somes (CCL) prepared in this way.
Some CCL formulations (those lacking PEG^
DSPE) would not migrate on a Sepharose CL-4B
column, possibly due to aggregation, and therefore
incorporation e⁄ciency was determined by separa-
tion on a discontinuous metrizamide gradient.
Twenty percent and 10% metrizamide were made
up in ddH2O and gradients were set up with 20%
in the bottom of the tube (2.5 ml), 10% in the middle
(7 ml) and 0% (2.5 ml) on top. Liposomes were
mixed with the 20% layer prior to set-up and then
tubes were centrifuged for 6^12 h at approximately
200 000Ug. Liposomes localized primarily at the
10%/0% interface.
3. Results
3.1. E¡ect of PEG^DSPE on passive entrapment of
asODN
The ¢rst set of experiments were performed in or-
der to determine the e¡ect of PEG^DSPE on the
incorporation e⁄ciency of asODN within the aque-
ous space of neutral liposomes (PELA). Passive in-
corporation has been used in the past to entrap
DNA or asODN in liposomes; however, the size of
liposomes produced and the incorporation e⁄ciency
are not often described in detail. Therefore, an e¡ort
was made to accurately describe the conditions, the
¢nal diameter, the incorporation e⁄ciency, the
asODN/lipid ratio and also the trapped volume of
liposomes produced.
The e¡ect of PEG^DSPE on asODN entrapment
e⁄ciency was examined for PC40/CHOL liposomes,
approximately 200 nm in diameter (Table 1). In or-
der to determine the percentage of asODN that may
Fig. 1. Bligh and Dyer extractions of 10 Wg 18-mer phosphoro-
thioate asODN using the cationic lipid DOTAP. Triangles rep-
resent asODN in the organic phase and circles represent
asODN remaining in the aqueous phase as determined by using
a radiotracer ([32P]asODN). Diamonds represent asODN re-
maining in the aqueous phase as determined by spectrophoto-
metric assay (mean þ standard deviation of three experiments).
(A) Amount of DOTAP expressed as nmol. (B) Amount of
DOTAP expressed as +/3 charge ratio.
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be associated with the liposome exterior, liposomes
were made by the method described, except asODN
was not included in the hydration bu¡er. AsODN
was added to the liposomal suspension just before
extrusion and then the mixture was separated on a
Sepharose CL4B column. Less than 1% of the added
asODN eluted with the lipid for all three groups (0,
2, 4 mol% PEG^DSPE) (data not shown). Therefore,
values for incorporation e⁄ciency presented in Table
1 can be taken to represent asODN mainly encapsu-
lated within the aqueous space of liposomes.
The results in Table 1 indicate that by adding
2 mol% or 4 mol% PEG^DSPE to PC40/CHOL lipo-
somes, the trapping e⁄ciency of asODN approxi-
mately doubled compared to liposomes lacking
PEG^DSPE. The incorporation data are also ex-
pressed as asODN to phospholipid ratios and as
trapped volumes to facilitate comparisons with other
published data. The trapped volumes were calculated
using radiolabeled asODN as the aqueous phase sol-
ute, and the results are consistent with the expected
values for liposomes of this size, prepared in this way
and suggest that the liposomes lacking PEG^DSPE
are multilamellar [24]. Subjecting the liposomes to
freezing and thawing did not increase the incorpora-
tion e⁄ciency of asODN within the aqueous space of
these liposomes.
3.2. Formation of hydrophobic asODN/DOTAP
particles
Reimer et al. described the formation of hydro-
phobic plasmid DNA^cationic lipid particles through
an organic extraction procedure [22]. They demon-
strated that cationic lipids could be used to extract
plasmid DNA from an aqueous phase, into an or-
ganic phase through a Bligh and Dyer monophase
[21]. The extraction was shown to be mediated by
the electrostatic interaction between the positively
charged lipid and the negatively charged DNA.
This procedure should also be applicable to nega-
tively charged asODN, and we hypothesized that
the hydrophobic particles in the organic phase could
be coated with neutral lipids through a reverse evap-
oration step. We predicted that this procedure would
result in liposomes having a high incorporation e⁄-
ciency for asODN. Furthermore, the addition of neu-
tral lipids, including PEG^DSPE, would serve to
coat the cationic lipid^asODN particles, adding
stability, decreasing the non-speci¢c adsorption of
serum proteins and increasing their circulation half-
lives.
The ¢rst step was to con¢rm that the extraction
procedure is applicable to asODN, and to determine
the amount of cationic lipid required for e⁄cient
extraction of the asODN into the organic phase.
Ten Wg of 18-mer phosphorothioate asODN (includ-
ing trace [32P]asODN) was extracted using 0^160
nmol DOTAP through a Bligh and Dyer monophase
as described in Section 2. Fig. 1 illustrates the results
from such an experiment and demonstrates that in-
creasing the amount of DOTAP increases the
asODN extracted from the aqueous phase into the
organic phase. When 40 nmol or more of DOTAP
was used, almost 100% of the asODN could be ex-
tracted (Fig. 1A). These data can be expressed in
terms of the +/3 charge ratio of DOTAP to asODN
phosphate as shown in Fig. 1B. Thirty nmol DOTAP
corresponds approximately to a 1:1 +/3 charge ratio
with 10 Wg asODN and at this ratio approximately
90% of the asODN was extracted into the organic
phase. When several replicates of the extraction were
done at a 1:1 charge ratio, 90^95% of the asODN
was extracted into the organic phase.
The assumption in this extraction procedure is that
it is the electrostatic interaction between the posi-
tively charged DOTAP and the negatively charged
asODN which drives the extraction. This is sup-
Table 1
Encapsulation of oligodeoxynucleotides within neutral liposomes containing increasing concentrations of PEG^DSPE
mol% PEG^DSPE Size
(nm)
Trapped volume
(Wl/Wmol PL)
Incorporation e⁄ciency
(%)
nmol asODN/Wmol PL
0 230 þ 10 1.0 þ 0.35 8 þ 3.2 0.6 þ 0.35
2 190 þ 12 2.5 þ 0.84 15 þ 7.7 1.6 þ 0.80
4 190 þ 15 2.3 þ 0.30 19 þ 3.6 1.4 þ 0.36
Each value represents the mean of three experiments þ S.D.
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ported by the work of Reimer et al. [22], and experi-
ments performed in our laboratory indicate that neu-
tral lipids do not result in the extraction of asODN
(data not shown). Experiments have also indicated
that the aqueous phase in which the asODN is dis-
solved plays an important role in the extraction e⁄-
ciency. Fig. 2 illustrates the results from a series of
extractions carried out using 60 Wg asODN and
0.15 Wmol DOTAP with the asODN diluted in
ddH2O, 10% sucrose, or 25 mM Hepes bu¡er con-
taining 140 mM NaCl (pH 7.4). At the DOTAP/
asODN ratio in this experiment (+/3= 0.88), more
than 80% of the asODN is extracted from the ddH2O
aqueous phase. When the asODN was dissolved in
10% sucrose approximately 70% of the asODN was
extracted from the aqueous phase, and the extraction
was completely inhibited when 25 mM Hepes, 140
mM NaCl (pH 7.4) was used as the aqueous phase.
This is likely caused by a charge-shielding e¡ect of
the Na and Cl3 ions preventing the e⁄cient inter-
action between the DOTAP and the asODN, since a
non-ionic solute such as sucrose had less of an e¡ect
on the extraction e⁄ciency.
3.3. Coated cationic liposome formation by reverse
phase evaporation
The size, and incorporation e⁄ciency were deter-
mined for CCL at di¡erent lipid ratios (Table 2).
Most CCL preparations were formed by extraction
of asODN into the organic phase at a 3.5:1 +/3
charge ratio, which ensured that nearly 100% of the
asODN would be extracted into the organic phase.
Following extraction of 50 Wg asODN with 0.5 Wmol
DOTAP, the organic phase was isolated and di¡erent
amounts of coating lipid were added (Table 2).
ddH2O was then added and the reverse evaporation
was carried out as described. After reversion into the
aqueous phase, no visible aggregates or precipitates
were present and particle diameter was in the 400^
500 nm range. Incorporation e⁄ciencies were in ex-
cess of 70%. The amount of coating lipid had no
e¡ect on the incorporation e⁄ciency, and very little
e¡ect on the liposome diameter for non-extruded
liposomes (Table 2). Changes in the asODN/PL ra-
tios in Table 2 simply re£ect di¡erences in the
amount of added coating lipid.
For many in vivo applications smaller diameter
liposomes would be advantageous, so the CCL
Fig. 3. Metrizamide gradient pro¢le for CCL containing
[3H]CHE as a lipid marker and [125I]asODN as a tracer. CCL
were composed of PC40/CHOL/DOTAP/PEG^DSPE (3.0:1.75:
0.5:0.175 Wmol). Gradients were fractionated by making a small
hole in the bottom of the plastic tube and collecting fractions
of equal drops. The ¢rst two fractions contained the majority
of the 20% metrizamide layer, while fractions 3^8 contained the
majority of the 10% layer. Closed circles represent lipid and
closed triangles represent asODN formulated in CCL. Plus-
marks are for a control showing the lack of migration of free
asODN on the gradient.
Fig. 2. Extraction by DOTAP (0.15 Wmol) of 60 Wg 18-mer
phoshorothioate asODN dissolved in di¡erent aqueous phases
(0.88 +/3 charge ratio). Extraction was determined by spectro-
photometric assay of the aqueous phase. 100% asODN in the
aqueous phase was determined by carrying out the extraction in
the absence of DOTAP. Values for asODN in the organic
phase were determined as the di¡erence between asODN in the
aqueous phase and total asODN added (100%). Each value rep-
resents the mean þ S.D. of three experiments.
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were extruded to reduce their size. We observed that
the amount of coating lipid added e¡ected our ability
to extrude CCL. When the PC40/DOTAP molar ra-
tio was less than 4:1, extrusion through 200-nm ¢l-
ters led to immediate aggregation and destabilization
(data not shown). However, at a PC40/DOTAP mo-
lar ratio of 3:1, CCL could be extruded through 200-
nm ¢lters when 5 mol% PEG^DSPE was included in
the coating lipids to prevent aggregation (Table 2).
Following extrusion through 200-nm polycarbonate
¢lters, the average diameter of CCL was 173 nm
(Table 2). Incorporation e⁄ciencies were determined
on a discontinuous metrizamide gradient (Fig. 3).
Free [125I]asODN remained at the bottom of the gra-
dient (20% metrizamide), while liposomes, along with
the loaded asODN, migrated to the 10%/0% inter-
face. For the experiment represented in Fig. 3, ap-
proximately 86% of the asODN migrated through
the gradient with the lipid fraction and the average
of three experiments is presented in Table 2.
Separation on a metrizamide gradient does not
discriminate between spurious association of asODN
with the liposome exterior and that in the aqueous
liposome interior. Therefore the amount of asODN
which could associate with the liposome exterior was
determined by making empty (without asODN) CCL
by the procedure outlined above, and then adding
asODN before separation on metrizamide gradients.
When formulated in this manner, approximately 50%
of the asODN bound to the liposome exterior and
migrated through the gradient with the lipid. How-
ever, when the liposomes are made in the absence of
asODN, a signi¢cant amount of DOTAP (i.e., pos-
itive charge) may be present in the outer phospholip-
id monolayer of the liposome and available for bind-
ing to asODN added to the liposome exterior. When
CCLs are made from extracted DOTAP/asODN par-
ticles, we propose that the DOTAP is sequestered
primarily in the liposome interior, associated with
asODN.
For in vivo applications, a carrier system lacking
excess positive charge would be desirable to reduce
MPS uptake. At a 1:1 +/3 charge ratio of DOTAP
to asODN phosphate, 90^95% of asODN was ex-
tracted into the organic; however, when neutral lip-
Table 2
Size and incorporation e⁄ciency of liposomes formed by the extraction^reverse evaporation procedure
PC40/CHOL/DOTAP/PEG^DSPE (Wmol) +/3 charge
ratio
Size (nm) Incorporation e⁄ciency
(%)
nmol asODN/Wmol PL
Not extruded
0.5:0.5:0.5:0 3.5 360 þ 60 72 þ 10 7.9 þ 2.1
1.0:0.75:0.5:0 3.5 530 þ 170 74 þ 4 5.4 þ 0.4
2.0:1.25:0.5:0 3.5 510 þ 200 73 þ 10 3.4 þ 0.5
Extruded
3.0:1.75:0.5:0.175 3.5 173 þ 4.2 86 þ 5 2.1 þ 0.1
3:2:1:0.2 1 219 þ 28 90 þ 9 17
Each value represents the mean þ S.D. of three experiments, except for the asODN/PL ratio for the last row, which is the result from
one experiment.
Fig. 4. Sepharose CL-4B column pro¢le of PELA and CCL in-
cubated at 37‡C for 24 h in 50% human plasma. [32P]asODN
was used as a tracer. Fractions 4^8 represent the lipid fractions
as determined by visual observation and by using [3H]CHE as
a lipid tracer (counts not shown). Closed squares represent
asODN passively entrapped within PC40/CHOL (2:1 molar)
liposomes containing 5 mol% PEG^DSPE, while closed circles
represent asODN formulated in CCL with the composition
PC40/CHOL/DOTAP/PEG^DSPE (3:2:1:0.2 molar). Closed di-
amonds represent free asODN (including [32P]asODN tracer) in-
cubated with 50% human plasma.
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ids were added without PEG^DSPE, lipid aggregates
formed during the reverse evaporation procedure. It
has been observed in other systems that signi¢cant
aggregation occurs as the +/3 charge ratio ap-
proaches 1 [25] and addition of PEG has been shown
to prevent aggregation and precipitation in these
electrostatic systems [26]. In the presence of 5 mol%
PEG^DSPE no aggregation was observed, and se-
quential extrusion through 200 nm ¢lters resulted
in an average particle diameter of 219 nm and an
incorporation e⁄ciency of 90% (Table 2).
3.4. E¡ect of plasma on stability and dissociation of
asODN
The stability of CCL and PELA in plasma-con-
taining medium at 37‡C was evaluated. CCL and
PELA were prepared at a 1:1 charge ratio DO-
TAP/asODN, and contained 5 mol% PEG^DSPE.
PELA had an average diameter of 185 þ 4 nm and
a 21% trapping e⁄ciency while the CCL had an aver-
age diameter of 190 þ 2 nm and a 80% trapping e⁄-
ciency. An aliquot from each group was diluted in an
Fig. 5. Schematic demonstrating the steps and hypothesized intermediate structures involved in making coated cationic liposomes
(CCL). (A) A mixture of chloroform and water exists as a biphase, with the upper aqueous phase (water) containing the asODN and
the lower organic phase (chloroform) containing the cationic lipid. (B) When methanol is added, a Bligh^Dyer monophase [21] is cre-
ated, allowing electrostatic interactions between the positively charged cationic lipid (black headgroups) and the negatively charged
asODN, which form micelle-like structures with the hydrophobic phospholipid tails facing the organic phase and the asODN seques-
tered inside. (C) The system reverts back into a biphase following the addition of chloroform and water with the hydrophobic
asODN-cationic lipid particles now concentrated in the organic phase. (D) The hydrophobic particles are used as intermediates in the
formation of liposomes through a reverse evaporation procedure [30]. The addition of neutral ‘coating lipids’ (white headgroups),
PEG and water followed by brief sonication will produce a ‘water-in-oil emulsion’ containing inverse micelles of the neutral lipids. (E)
Following evaporation of the chloroform, an intermediate gel phase is reached and further evaporation causes inversion of the mi-
celles, which will coat the cationic lipid^asODN-particles (F) leaving CCL in an aqueous solution, sterically stabilized with PEG.
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equal volume of human plasma and the samples were
incubated at 37‡C for 24 h. No increase in diameter
was observed for either preparation. Following frac-
tionation of each preparation on Sepharose CL-4B
columns, the asODN eluted almost exclusively with
the liposomes in the void volume (Fig. 4). These
results demonstrate that both formulations were
able to maintain their size and stability with minimal
leakage of asODN in plasma-containing media.
4. Discussion
In this study we examined the physical character-
istics (diameter, stability) and incorporation e⁄-
ciency of two di¡erent liposomal formulations of
asODN which may be suitable for in vivo applica-
tions. Cationic lipoplexes are not suitable for sys-
temic administration due to their large size and ex-
cess positive charge which leads to their rapid
removal from circulation, primarily into liver and
lung. Pharmacokinetic studies have demonstrated
that cationic lipoplexes are unable to deliver asODN
to tissues other than the MPS and lung [27,28].
Passive encapsulation within neutral liposomes is
an alternative to using cationic lipoplexes; however,
our results con¢rm that this is an ine⁄cient process
and only a fraction of the added asODN is loaded.
An unexpected ¢nding was that the incorporation
e⁄ciency of an 18-mer phosphorothioate asODN
was increased by the addition of 2^5 mol% PEG^
DSPE. This may be a result of an increased trapped
volume due to decreased lamellarity of the liposomes
and while it is an interesting observation, the incor-
poration e⁄ciency obtained was still quite low (20%).
It is di⁄cult to compare the incorporation e⁄cien-
cies observed in our study with previously published
results. As mentioned in the Introduction, few stud-
ies give su⁄cient details to properly characterize the
encapsulation of asODN within neutral liposomes.
For example, Thierry et al. report incorporation e⁄-
ciencies of 50^70% of added asODN. However, the
size of the liposomes is not reported and small size is
an important consideration for in vivo applications
[5,16].
Neutral PEG-containing liposomes have longer
circulation half-lives in vivo than cationic lipoplexes
lacking PEG [11,18,27^29]. However, as described
above, these liposomes have poor incorporation e⁄-
ciencies. Therefore, we developed a CCL formulation
that combines the bene¢ts of neutral liposomes, such
as stability and long circulation times, with the high
incorporation e⁄ciency of asODN obtained with cat-
ionic lipoplexes. CCL are produced in a two step
process in which asODN are ¢rst complexed with
cationic lipid at a 1:1 charge ratio, followed by a
coating procedure in which neutral lipids (with or
without PEG^DSPE) are added to produce coated
cationic liposomes. CCL can be extruded to diame-
ters below 200 nm, they are stable in plasma and
have incorporation e⁄ciencies of around 90%. Our
results indicate that asODN can be extracted
through a Bligh and Dyer monophase into an organ-
ic phase using cationic lipid, similar to the extraction
of plasmid DNA as described by Reimer et al. [22].
These cationic lipid^asODN hydrophobic complexes
serve as useful intermediates in the formation of
CCL through a reverse evaporation procedure.
The exact structure of the hydrophobic particles
produced by the extraction procedure is unknown,
but we can make a prediction (Fig. 5). In order for
the asODN to exist in a hydrophobic environment
such as CHCl3, it must be shielded by the lipid, pos-
sibly in the form of an inverted micelle (Fig. 5C).
This structure serves as a useful intermediate in the
formation of liposomes through a reverse phase
evaporation method similar to that described by Szo-
ka and Papahadjopoulos [30]. The outline for such a
procedure is described in Fig. 5C^F. By formulating
the asODN and cationic lipid in this way, we are
attempting to sequester a majority of the cationic
lipids and the asODN within a coating of neutral
and PEG-modi¢ed lipids. In this way, the cationic
lipid serves to e⁄ciently load the asODN, but is
not available for interaction with cells or serum pro-
teins. This model for CCL formation is supported
by our results demonstrating a lack of aggregation
or release of asODN in the presence of human plas-
ma (Fig. 4). Similarly, PELA did not aggregate or
leak; however, this is not surprising since these lipo-
somes contain 5 mol% PEG^DSPE and no cationic
lipid.
Very recently, other formulations have been devel-
oped which attempt to incorporate some of these
characteristics into a liposomal carrier for asODN,
for example, the LPDII particles described by Li et
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al. [31]. LPDII particles are 150^200 nm in diameter
and entrap approximately 60% of added asODN;
however, their stability or activity in the presence
of plasma have not been demonstrated. Meyer et
al. mixed asODN with pre-formed liposomes com-
posed of DOPE, PEG^PE and a cationic lipid [32].
The authors report very good incorporation with a
high asODN/lipid ratio and suggest that the com-
plexes are stable in plasma. However, roughly 40%
of the asODN dissociated from liposomes upon in-
cubation in 50% plasma, and pharmacokinetic ex-
periments indicated that even more dissociation oc-
curs upon intravenous injection (D. Kirpotin,
personal communication). This is probably a result
of asODN, associated with the outside of the lipo-
somes, dissociating in plasma. Our experiments indi-
cate that up to 50% of asODN added to the outside
of CCL, formed in the absence of asODN, would
bind to the CCL and could dissociate. However,
when CCL were formed with asODN present during
the extraction we observed no dissociation of the
asODN in plasma, suggesting that the asODN is
sequestered in the interior of the liposomes in asso-
ciation with the cationic lipid (Fig. 5F).
In the CCL formulation we used a charge neutral
ratio of DOTAP/asODN and added 5 mol% PEG^
DSPE in order to prevent aggregation and decrease
adsorption of serum proteins and interaction with
non-target cells. This is in contrast to typical cationic
lipid^asODN complexes which carry an excess pos-
itive charge and results in non-speci¢c interactions
with most cell types. Experiments in our laboratory
indicate that cells treated with LipofectAMINE^
asODN complexes take-up more asODN than cells
treated with asODN formulated in CCL. However,
when CCL are targeted by coupling a monoclonal
antibody to the surface, the levels of cell associated
asODN are increased signi¢cantly, and approach lev-
els observed following treatment delivery using Lipo-
fectAMINE. In a mixed cell population, for example
in vivo, it would be an advantage to use an asODN
carrier which has selectivity for the target cell pop-
ulation, rather than one which interacts non-speci¢-
cally (albeit e⁄ciently) with all cell types encoun-
tered.
Over the past decade, it has become apparent that
liposomes which are able to circulate in the blood-
stream, without rapid uptake into the liver or spleen,
may be able to passively target sites of disease such
as solid tumors and sites of infection [12,33^38]. A
separate manuscript (submitted for publication) dem-
onstrates that the CCL formulation has long-circu-
lating pharmacokinetics similar to PELA and there-
fore may be able to take advantage of this passive
targeting e¡ect. Other studies have demonstrated
that enhanced circulation times are required for li-
gand-mediated targeting of liposomes [39] and this
targeting has been shown to result in enhanced anti-
tumor activity when the liposomes are loaded with
doxorubicin [13,15]. The CCL formulation can also
be targeted to a speci¢c cell type by adding a cou-
pling lipid (e.g., 4-(p-maleimidophenyl)butyrate^
PEG^DSPE) to the coating lipids and attaching a
targeting ligand following CCL formation. Another
paper (submitted for publication) demonstrates that
antibody-targeted CCL (and to a lesser extent non-
targeted CCL) are e¡ective at delivering a c-myb
asODN resulting in an antiproliferative e¡ect in a
glioblastoma cell line.
Signi¢cant progress has been made in recent years
in bringing asODN into the clinical setting and there
are several early to mid-phase clinical trials using
asODN to treat diseases ranging from cancer, to hu-
man immunode¢ciency virus infection (HIV) to in-
£ammatory conditions. However, only one asODN
has received approval for marketing in the United
States and that is a phosphorothioate anti-cytomeg-
alovirus^asODN used to treat CMV retinitis in
AIDS patients [40]. The anti-CMV^asODN is ad-
ministered via local (intravitreal) injection and is
not subject to signi¢cant redistribution via the blood-
stream. However, the intravenous route of adminis-
tration will be most convenient for asODN targeted
to other diseases such as cancer or HIV infection and
in these situations, the activity of the asODN may be
signi¢cantly improved by the use of a well-designed
liposomal carrier. The CCL formulation that we
have described meets many of the requirements of
a useful drug carrier and could signi¢cantly increase
the therapeutic activity of asODN.
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